Previous Close | 2.9000 |
Open | 2.9000 |
Bid | 2.6000 |
Ask | 2.9500 |
Strike | 7.00 |
Expire Date | 2026-01-16 |
Day's Range | 2.9000 - 2.9000 |
Contract Range | N/A |
Volume | |
Open Interest | 1.23k |
ROCKVILLE, Md. & EDMONTON, Alberta, June 14, 2024--Aurinia Announces 2024 Annual General Meeting Results
Key Insights Aurinia Pharmaceuticals will host its Annual General Meeting on 14th of June CEO Peter Greenleaf's total...
ROCKVILLE, Md. & EDMONTON, Alberta, June 05, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with active